TABLE 11Impact of Detecting Non-Adenomas on Incremental Cost-Effectiveness Ratios Study

StrategyHarvardLadabaumMiscanVijanVanderbilt (old)Vanderbilt (new)
F/S$99,977$79,920$55,878$56,969$355,647$355,608
SSDSDSDSDSDSD
RWDSDWDSD$209,906$114,510
CSDSDSDSDWDSD
F$11,632$7,272$5,980$9,676$10,073$8,659

NOTES: F/S = annual fecal occult blood test, sigmoidoscopy every 5 years; S = sigmoidoscopy every 5 years; R = prototype radiology procedure every 5 years; C = colonoscopy every 10 years; F = annual fecal occult blood test; WD = strategy is weakly dominated by at least one other strategy; and SD = strategy is strongly dominated by at least one other strategy.

SOURCE: R. Ness Workshop Presentation (Appendix G).

From: THE COLLABORATIVE MODELING EXERCISE

Cover of Economic Models of Colorectal Cancer Screening in Average-Risk Adults
Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary.
Institute of Medicine (US); National Research Council (US); Pignone M, Russell L, Wagner J, editors.
Washington (DC): National Academies Press (US); 2005.
Copyright © 2005, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.